Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | mitogen activated protein kinase 11 | 0.0907 | 0.2995 | 0.2995 |
Loa Loa (eye worm) | hypothetical protein | 0.075 | 0.2395 | 0.2385 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.0913 | 0.302 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 14 | 0.0907 | 0.2995 | 0.2995 |
Schistosoma mansoni | hypothetical protein | 0.0929 | 0.308 | 1 |
Onchocerca volvulus | 0.0929 | 0.308 | 0.1689 | |
Brugia malayi | Matrixin family protein | 0.1825 | 0.6509 | 1 |
Loa Loa (eye worm) | matrixin family protein | 0.1662 | 0.5886 | 0.8847 |
Onchocerca volvulus | Matrilysin homolog | 0.181 | 0.6449 | 1 |
Loa Loa (eye worm) | matrixin family protein | 0.1825 | 0.6509 | 1 |
Trypanosoma brucei | mitogen-activated protein kinase 3, putative | 0.0907 | 0.2995 | 0.5 |
Brugia malayi | P38 map kinase family protein 2 | 0.0907 | 0.2995 | 0.1459 |
Loa Loa (eye worm) | CMGC/MAPK/P38 protein kinase | 0.0907 | 0.2995 | 0.3496 |
Loa Loa (eye worm) | hypothetical protein | 0.0897 | 0.2958 | 0.3427 |
Loa Loa (eye worm) | hypothetical protein | 0.075 | 0.2395 | 0.2385 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.2738 | 1 | 1 |
Mycobacterium ulcerans | hydrolase | 0.0913 | 0.302 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 11 | 0.0907 | 0.2995 | 0.2995 |
Echinococcus multilocularis | mitogen activated protein kinase 11 | 0.0907 | 0.2995 | 0.2995 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.1662 | 0.5886 | 0.8611 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0907 | 0.2995 | 0.5 |
Schistosoma mansoni | matrix metallopeptidase-7 (M10 family) | 0.0897 | 0.2958 | 0.9566 |
Loa Loa (eye worm) | hypothetical protein | 0.0913 | 0.302 | 0.3541 |
Loa Loa (eye worm) | matrix metalloproteinase | 0.075 | 0.2395 | 0.2385 |
Leishmania major | mitogen-activated protein kinase 3, putative,map kinase 3, putative | 0.0907 | 0.2995 | 0.5 |
Echinococcus multilocularis | adam 17 protease | 0.0196 | 0.028 | 0.028 |
Echinococcus granulosus | adam 17 protease | 0.0216 | 0.0355 | 0.0355 |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.0913 | 0.302 | 0.5 |
Brugia malayi | Matrix metalloprotease, N-terminal domain containing protein | 0.0913 | 0.302 | 0.1518 |
Echinococcus multilocularis | mitogen activated protein kinase 14 | 0.0907 | 0.2995 | 0.2995 |
Schistosoma mansoni | matrix metallopeptidase-9 (M10 family) | 0.06 | 0.1824 | 0.5516 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0907 | 0.2995 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 14 | 0.0907 | 0.2995 | 0.2995 |
Brugia malayi | Hemopexin family protein | 0.0929 | 0.308 | 0.1664 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 11 nM | In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 2 expressed in CCL39 cells; (n=3) | ChEMBL. | 15828816 |
IC50 (binding) | = 114 nM | In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 5 expressed in CHO-K1 cells; (n=3) | ChEMBL. | 15828816 |
IC50 (binding) | = 389 nM | In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 3 expressed in CCL39 cells; (n=3) | ChEMBL. | 15828816 |
IC50 (binding) | > 10000 nM | In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 1 expressed in CHO-K1 cells; (n=3) | ChEMBL. | 15828816 |
IC50 (binding) | > 10000 nM | In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 4 expressed in CCL39 cells; (n=3) | ChEMBL. | 15828816 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.